Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Prepaid Assets: 2020-2025

Historic Prepaid Assets for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $31.6 million.

  • Apellis Pharmaceuticals' Prepaid Assets rose 32.55% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.6 million, marking a year-over-year increase of 32.55%. This contributed to the annual value of $18.4 million for FY2024, which is 52.68% down from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Prepaid Assets stood at $31.6 million, which was up 8.19% from $29.2 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Prepaid Assets ranged from a high of $73.4 million in Q1 2022 and a low of $18.4 million during Q4 2024.
  • In the last 3 years, Apellis Pharmaceuticals' Prepaid Assets had a median value of $34.4 million in 2023 and averaged $33.3 million.
  • In the last 5 years, Apellis Pharmaceuticals' Prepaid Assets skyrocketed by 162.95% in 2021 and then crashed by 52.68% in 2024.
  • Apellis Pharmaceuticals' Prepaid Assets (Quarterly) stood at $70.7 million in 2021, then tumbled by 48.13% to $36.7 million in 2022, then climbed by 5.90% to $38.8 million in 2023, then slumped by 52.68% to $18.4 million in 2024, then surged by 32.55% to $31.6 million in 2025.
  • Its last three reported values are $31.6 million in Q3 2025, $29.2 million for Q2 2025, and $37.1 million during Q1 2025.